ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core...
Transcript of ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core...
![Page 1: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/1.jpg)
ASTRO Refresher Course 2016
Breast Cancer
Jennifer R. Bellon, M.D.
Dana-Farber Cancer Institute
Associate Professor of Radiation Oncology
Harvard Medical School
![Page 2: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/2.jpg)
I have no relevant conflicts of interest
![Page 3: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/3.jpg)
Breast Conservation for Invasive Disease
• Anatomy
• Selection for BCT and modern outcomes
• Substituting hormonal therapy for RT
• Shortening the RT course
–Update on hypofractionation
–Accelerated Partial Breast Irradiation
![Page 4: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/4.jpg)
Outline (continued)
• Management of the regional nodes
– Axillary dissection with a positive sentinel
node
– RT fields (SCV/IM)
• PMRT
• RT after preoperative systemic therapy
• Update on DCIS
![Page 5: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/5.jpg)
IM nodes
Axillary
nodes
![Page 6: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/6.jpg)
Selection of Patients for BCT
• Imaging
– U/S, spot compression for densities
– Magnification views for calcifications
– MRI (selected cases only)
• Tissue diagnosis
– Core biopsy (not FNA)
– Excisional biopsy if core biopsy not feasible
• Breast-conserving surgery
– Careful evaluation of margins
– Post-excision mammogram for residual Ca++
![Page 7: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/7.jpg)
Use of Breast MRI at Diagnosis
Not Established Established
Fewer re-excisions Finds multicentric dx
Decreased LR More delays
Improved survival More biopsies
Increased costs
More mastectomies
Houssami Ann Surg 2013
Turnbull Lancet 2010
![Page 8: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/8.jpg)
Selection of Patients for BCT
• Contraindications:
– Multicentric disease
– Prior RT
– Pregnancy
– Positive margins (in breast tissue)
– ? Collagen vascular disease
• BRCA 1/2 mutation carriers – future risk
• Impact of biologic subtype
• What constitutes an adequate margin?
ACOSOG Z11102
RTOG 1014
![Page 9: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/9.jpg)
Reduction in Local Recurrence with RT
CS CS + RT Reduction
NSABP B-06 36% 12% 67%
Uppsala-Orebro 24% 9% 63%
Ontario 35% 11% 69%
Milan 24% 6% 75%
Swedish 14% 4% 71%
![Page 10: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/10.jpg)
EBCTCG: Impact of Radiation on LRR
EBCTCG Lancet 2011 378(9804):1707-16
N=10801 in 17 randomized trials
![Page 11: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/11.jpg)
How Are We Doing?
• Local recurrence <5% at 10 years
– Improved imaging
– More detailed pathologic examination of
the specimen
– Improved systemic therapy
• Both improves LR, and also makes LR more
important (by controlling micrometastatic
disease)
• Heterogeneity of outcomes by subtype
![Page 12: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/12.jpg)
Subtype is Prognostic for LR
HER2 (No Herceptin)
Triple -
Lum B
Lum A
Lum-HER2
No herceptin
Arvold N et al. JCO 2011; 29(29)
![Page 13: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/13.jpg)
Meta-Analysis of LRR by Subtype
• N=12,592
– BCT 57%
– Mastectomy 43%
• RT in all BCT patients and 44% of
mastectomy patients
• Chemotherapy, 48%
• Herceptin in HER2-positive patients, 6%
Lowery et al. Breast Ca Res Treat 2012; 133: 831-41
![Page 14: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/14.jpg)
Meta-Analysis: LRR after BCT
Lowery et al. Breast Ca Res Treat 2012; 133: 831-41
RR 0.49
![Page 15: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/15.jpg)
Meta-Analysis: LRR After Mastectomy
Lowery et al. Breast Ca Res Treat 2012; 133: 831-41
RR 0.66
![Page 16: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/16.jpg)
BCT vs. Mastectomy
• Retrospective series from Alberta
• N =768; BCT, MRM or MRM+RT
• Higher-risk pts had MRM or MRM+RT
• LRR at 5 years– BCT 6%
– MRM 15%
– MRM+RT 13%
• MVA: MRM, LVI and nodal positivity
predicted LRR; chemo protective
Abdulkarim et al. JCO 2011; 29
![Page 17: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/17.jpg)
LRR in T1/T2, N0 Subset (No RT after MRM; 35% chemotherapy)
T1/T2, N0 unmatched
P=0.022
T1/T2, N0 matched for
tumor size
P=0.039
Abdulkarim et al. JCO 2011; 29
96%
90%
![Page 18: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/18.jpg)
Wider Margins for TNBC?
• Retrospective review; n=535
– Margins <2 mm: 71 patients
– Margins >2 mm: 464 patients
• Median follow-up 84 months; 84% received
chemotherapy
• Cumulative incidence of LR at 60 months
– 4.7% for close margins
– 3.7% for wide margins; p=NS
Pilewskie M et al. Ann Surg Oncol 2014; 21(4)
![Page 19: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/19.jpg)
TNBC: Is BCT Appropriate?
• Comfort in these results, despite
selection bias
– BCT remains standard treatment in
otherwise appropriate patients
• Likely biology, not extent of surgery, is
the driving factor
• Raises question of RT for high-risk node
negative TNBC after mastectomy
![Page 20: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/20.jpg)
Margins
![Page 21: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/21.jpg)
Goals of Margin Evaluation
• To identify patients more likely to have
a large residual tumor burden that can’t
be controlled by modern systemic
therapy and RT
– need re-excision or mastectomy
![Page 22: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/22.jpg)
Why not just re-excise?
• Extent of excision most important determinant of cosmetic outcome
• Re-excisions associated with:
- Patient anxiety
- Worse cosmetic outcome
- Morbidity
- Cost
- Patients opting for mastectomy
![Page 23: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/23.jpg)
Margins Meta-Analysis (Basis for ASTRO-SSO Consensus)
• 33 studies, invasive cancer, 1979 – 2001
• N = 28,162; 1506 LRs
• Follow up: 79 months (range: 48-160)
• Series reports used
– not individual patient data
• Does not apply to: no RT, neoadjuvant,
APBI, pure DCIS
Houssami N, et al. Ann Surg Oncol 2014; 21: 717-730
![Page 24: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/24.jpg)
Margins Meta-Analysis
Margins and LR (adjusted for length of FU)
OR 95% CI p-value
Margin status
Negative 1.0 < .001
Positive/Close 1.96 1.72-2.24
Margin status
Negative 1.0
“Close” 1.74 1.42-2.15
“Positive” 2.44 1.97-3.03 < 0.001
Increased local recurrence rate associated with positive margins not nullified by
radiation boost, systemic therapy, or favorable biology
Houssami N, et al. Ann Surg Oncol 2014; 21: 717-730
![Page 25: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/25.jpg)
Margins Meta-AnalysisRelationship Between LR and Margin
Threshold Distance#
studies#LRs/#subjects OR* 95% CI
1 mm 6 235/2376 1.0
2 mm 10 414/8350 0.91 0.46-1.80
5 mm 3 103/2355 0.77 0.32-1.88
* Adjusted for length of FU p (association) = 0.90
p (trend) = 0.58
Houssami N, et al. Ann Surg Oncol 2014; 21: 717-730
![Page 26: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/26.jpg)
ASTRO-SSO Margins Consensus: Summary
• Negative margins (no ink on tumor) optimizes local
control
• Positive margin associated with at least a 2-fold
increased risk of LR
– Not nullified by the boost, systemic therapy, or favorable
biology
• Wider margin widths do not significantly improve local
control
• The routine practice of obtaining margins more widely
clear than no ink on tumor is not indicated
J Clin Oncol. 2014 May 10;32(14):1507-15
![Page 27: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/27.jpg)
Boost
![Page 28: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/28.jpg)
EORTC Boost
• Stage I/II; n=5318
• Microscopic complete resection
– For invasive disease only
• Randomization:
– 50 Gy whole breast
– 50 Gy whole breast + 16 Gy boost
• Median follow-up 17.2 years
Bartelink H, et al. Lancet Oncol. 2015 Jan;16(1):47-56
![Page 29: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/29.jpg)
EORTC Boost: 20-Year Results
• Ipsilateral breast tumor recurrence as a
first event 16.4% vs 12.0%
– HR 0.65; 99% CI 0.52–0.81, p<0·0001
• No difference in distant metastases-
free survival or overall survival
• Severe fibrosis 5.2% vs 1.8%, p<0.0001
• Any fibrosis 71.4% vs 57.2%. P<0.001
Bartelink H, et al. Lancet Oncol. 2015 Jan;16(1):47-56
![Page 30: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/30.jpg)
Local Recurrence by Age
<40
51-60
41-50
>60
Bartelink H, et al. Lancet Oncol. 2015 Jan;16(1):47-56
![Page 31: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/31.jpg)
Omission of Radiation
![Page 32: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/32.jpg)
NSABP B-21: BCT in Tumors < 1.0 cm
• N=1009, T1a,1b N0
• Randomized to RT + placebo, Tam,
Tam + RT
• Only 54-59% known to be ER+
• RT 50 Gy whole breast; boost optional
(20%)
Fisher et al, J Clin Oncol. 2002 Oct 15;20(20):4141-9
![Page 33: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/33.jpg)
Bernard Fisher et al. JCO 2002;20:4141-4149
IBTR by Treatment Arm
All comparisons p<0.05
17%
9%
3%
![Page 34: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/34.jpg)
Omission of Radiation: CALGB 9343
• Randomized trial of tamoxifen alone or
tam with radiation in women over 70
• Axillary dissection discouraged– 37% dissection; 63% no axillary surgery
– All clinically node negative
• RT 45 Gy whole breast + 14 Gy boost
• Median follow-up 12.6 years
Hughes KS et al JCO 2013, 45: 2615
![Page 35: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/35.jpg)
CALGB 9343: Results at 10 Years
NLRR Free
Survival (%)
DM Free
Survival (%)
Overall
Survival (%)
Mastectomy Free
Survival (%)
TAM 319 90 95 66 96
TAM +
RT317 98* 95 67 98
* P<.001; HR 0.18
Not able to assess subtleties in risk groups (LVI, grade))
Hughes KS et al JCO 2013, 45: 2615
![Page 36: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/36.jpg)
PRIME II: RT + Hormonal therapy vs
Hormonal therapy alone
• RT + hormonal therapy vs hormonal
therapy alone
• Age greater than 65
• < 3.0 cm, N0
• HR positive
• Margins >1 mm (CALGB no ink on
tumor)
• Grade 3 or LVI permitted (not both)
Kunkler I, Lancet Oncol. 2015 Mar;16(3):266-73
![Page 37: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/37.jpg)
PRIME II: 5-year Results
RT NO RT P
IBTR (%) 1.3 4.1 0.001
DM (%) .3 1.0 NS
OS (%) 94.2 93.8 NS
Kunkler I, Lancet Oncol. 2015 Mar;16(3):266-73N=1326
![Page 38: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/38.jpg)
Omission of Radiation Princess Margaret Hospital
• Phase III, randomized trial
• RT + TAM vs TAM alone
• Eligibility
– 50 and older
– T1, T2
– Path node negative if younger than 65 (clinically node negative if older than 65)
Fyles, A. et al. NEJM 2004;351:963-970
![Page 39: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/39.jpg)
PMH Stratification
• Tumor size (<2.0 cm, >2.0 cm)
• ER (positive, negative or unknown)
• Participating center
• Method of determining axillary
status in women over 65 (clinical or
surgical)
Fyles, A. et al. NEJM 2004;351:963-970
![Page 40: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/40.jpg)
Patient
Characteristics
(n=769)
Fyles, A. et al. NEJM 2004;351:963-970
![Page 41: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/41.jpg)
Patient
Characteristics
(n=769)
Fyles, A. et al. NEJM 2004;351:963-970
![Page 42: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/42.jpg)
Patient
Characteristics
(n=769)
Fyles, A. et al. NEJM 2004;351:963-970
![Page 43: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/43.jpg)
Cumulative Incidence of Local Relapse
Fyles, A. et al. NEJM 2004;351:963-970
8 –yr LR: 17.6% vs 3.5%
PMH: Time to Local Recurrence
![Page 44: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/44.jpg)
Fyles AW et al. N Engl J Med 2004;351:963-970
Disease-free Survival.Disease-Free Survival
No difference in OS
93.2% vs 92.8%
![Page 45: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/45.jpg)
RT for Luminal A Disease?
• Subset of 304 patients
• Approximation of intrinsic molecular subtyping
ER, PR, Ki-67, Her2, EGFR and CK5/6
– Luminal A (+/+/-, Ki67<14%) and grade I/II; n=114)
– Luminal B (+/+/-, Ki67>14%; n=82)
Liu et al JCO, 33 (18), 2015
![Page 46: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/46.jpg)
Response to RT by Subtype
Liu et al JCO, 33 (18), 2015
Luminal A
Luminal B
"unfavorable subtypes"
![Page 47: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/47.jpg)
Three Hormonal Therapy Alone
Prospective Single-Arm Trials
Premise:
There exists a subset of patients with
early-stage disease with such a low
likelihood of recurrence such that
radiation can be safely omitted
![Page 48: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/48.jpg)
PRECISION (DFCI)
• Age 50-75
• Unifocal, <2.0 cm
• Node negative (path); N0i+ permitted
• ER positive, PR positive, HER2 negative
– Grade I/II
– Luminal A by PAM50
• Eligible and willing to receive endocrine therapy
• Accrual goal: 345
ClinicalTrials.gov
NCT02653755
![Page 49: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/49.jpg)
LUMINA (Ontario Clinical Oncology Group)
• T1N0
• Grade I or II and Ki67 < 13.25% (luminal A)
• Age >55
• Margins > 1 mm
• No lobular cancers, No EIC
• Accrual goal: 500
ClinicalTrials.gov
NCT01791829
![Page 50: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/50.jpg)
Individualized Decisions for Endocrine
Therapy Alone (IDEA)
• Multicenter, led by University of Michigan
• T1N0 (i+ allowed)
• ER+/PR+/HER2 neg
• Age 50-69
• Oncotype <18
• Minimum 5 years of endocrine therapy
• Accrual goal: 200
ClinicalTrials.Gov
NCT02400190
![Page 51: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/51.jpg)
Hypofractionation
![Page 52: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/52.jpg)
Ontario Clinical Oncology Group Trial
• 1234 patients randomized to:50 Gy/2 Gy fx/35 days
vs
42.5 Gy/16 fx/22 days
• T1 – T2 tumors; all node negative
• Large breasted women excluded (separation > 25 cm)
• Non-inferiority with 80% power to rule out 5% increase in local recurrence
Whelan et al, J Natl Cancer Inst 2002, 94(15):1143-50
![Page 53: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/53.jpg)
Whelan et al: Results
Median follow-up:
12 years
Tam : 41%
Chemo: 11%
Whelan et al NEJM 362 (6), 2010
![Page 54: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/54.jpg)
Long-term Toxicity
Whelan TJ, NEJM 2010; 362:513-20
No difference in skin/subcutaneous toxicities
Late Effects of Radiation
![Page 55: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/55.jpg)
Long Term Cosmetic ResultsGlobal Cosmetic Outcome, Assessed According to the EORTC Scale.
Whelan TJ et al. N Engl J Med 2010;362:513-520
No difference in long-term cosmetic result
![Page 56: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/56.jpg)
UK Start B
• N=2215
• Median follow-up: 9.9 years
• Standard Arm:
– 2 Gy per fraction
– 25 fractions/5 weeks
• Experimental arm:
– 2.66 Gy per fraction
– 15 fractions/3 weeks
Haviland JS et al. Lancet Oncology (14), 2013
![Page 57: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/57.jpg)
Start B: Cumulative Incidence LRR
50 Gy
40 Gy
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
0 1 2 3 4 5 6 7 8 9 10
Time from randomisation (years)
LRR
0
HR .77 (0.51-1.116); p=0.21
Haviland JS et al. Lancet Oncology (14), 2013
![Page 58: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/58.jpg)
Start B: Marked/Moderate Cosmetic Defect
% of patients with no
moderate / marked
effect
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10
Time from randomisation (years)
40 Gy
50 Gy
HR .77 (.66-.89)
Haviland JS et al. Lancet Oncology (14), 2013
![Page 59: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/59.jpg)
Fig. 1. Rates of hypofractionation use by institution for patients with T1-2, N0 tumors treated with lumpectomy and whole-breast
radiation therapy (n=913).
Jagsi et al, IJROBP Volume 90, Issue 5, 2014, 1010–1016
Use of Hypofractionation by Institution(October, 2011 - December, 2013)
Total:
31%
![Page 60: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/60.jpg)
Hypofrac vs Conventional: MDACC
50 Gy/25 fx + 10-14 Gy/7 fx (n=149)
Vs
42.56 Gy/16 + 10-12.5 Gy/4-5 fx (n=138)
Eligibility
40 or older
Stage 0-2
Breast only radiation
Shaitelman et al, JAMA Oncol. 2015;1(7):931-941
![Page 61: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/61.jpg)
Primary Objectives
• MD-reported acute and 6-month
toxicity
– NCI-CTC
• Patient reported QOL at 6 months
– Functional assessment of cancer
therapy for patients with breast cancer
(FACT-B)
Shaitelman et al, JAMA Oncol. 2015;1(7):931-941
![Page 62: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/62.jpg)
Key Patient/Treatment Characteristics
• 79% C cup or larger
• 25% sep > 25.6
• 76% overweight or obese
• Prone or supine permitted
• Multiple subfields encouraged to maximize homogeneity
– 75% dmax < 107.7%
Shaitelman et al, JAMA Oncol. 2015;1(7):931-941
![Page 63: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/63.jpg)
Max MD-reported
acute toxic effect
Not significant:
Wound complications
Breast infection
Skin ulceration
Seroma
UE edema
Shaitelman et al, JAMA Oncol. 2015;1(7):931-941
![Page 64: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/64.jpg)
6-months Results
• Physician-reported fatigue:
– 0% HF vs 6% CF (p=0.01)
• Patient reported lack of energy:
– 23% HF vs 39% CF (p=<0.001)
• Trouble meeting family needs:
– 3% HF vs 9% CF (p=0.01)
Shaitelman et al, JAMA Oncol. 2015;1(7):931-941
![Page 65: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/65.jpg)
Predictors of Lack of Energy at 6 Months
n OR p
Randomization Conventional 140 1
Hypofrac 128 0.39 <0.001
Age 40-49 27 1
50-59 97 1.10 .83
60-69 104 1.92 .13
70 and older 40 2.39 .08
BMI <24.5 68 1
24.5 – 29.1 70 0.88 0.72
29.2 – 33.6 66 1.60 0.25
>33.6 64 1.02 0.97
Tumor behavior Invasive 69 1
Non-invasive 70 0.56 0.07
Shaitelman et al, JAMA Oncol. 2015;1(7):931-941
![Page 66: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/66.jpg)
Predictors of Lack of Energy at 6 Months
n OR p
Randomization Conventional 140 1
Hypofrac 128 0.39 <0.001
Age 40-49 27 1
50-59 97 1.10 .83
60-69 104 1.92 .13
70 and older 40 2.39 .08
BMI <24.5 68 1
24.5 – 29.1 70 0.88 0.72
29.2 – 33.6 66 1.60 0.25
>33.6 64 1.02 0.97
Tumor behavior Invasive 69 1
Non-invasive 70 0.56 0.07
Shaitelman et al, JAMA Oncol. 2015;1(7):931-941
![Page 67: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/67.jpg)
Hypofractionation
Hypofractionation is rapidly becoming standard of care for most women treated with breast conserving surgery and whole breast radiation
Note only is long-term LR similar, but now we have convincing data that short-term toxicity and QOL is improved, and long-term toxicity isn't compromised
![Page 68: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/68.jpg)
Unanswered Questions
• Is the biology the same in all subgroups?
– Triple negative?
– DCIS?
• What is the optimal
dose/fractionation/boost?
• What about chest wall/nodal irradiation?
– Brachial plexopathy? Lymphedema???
![Page 69: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/69.jpg)
Other Hypofractionation Trials
• IMPORT High (UK)
– 2.4 Gy x 15 fx (integrated boost)
– 2.67 Gy x 15 fx (sequential boost)
– Accrual goal 840
• FAST (UK)
– 2 Gy x 25 fx
– 5.7 Gy x 5 fx
– 6 Gy x 5 fx
All in 5 weeks
![Page 70: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/70.jpg)
TROG Trial for DCISAccrual goal 1600
• Conventional fractionation, no boost
– 50 Gy, 25 fractions
• Conventional fractionation, boost
– 50 Gy, 25 fractions + 16 Gy, 8 fractions
• Hypofractionated, no boost
– 42.5 Gy, 16 fractions
• Hypofractionated, boost
– 42.5 Gy 16 fractions + 16 Gy, 8 fractions
![Page 71: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/71.jpg)
RTOG 1005
Randomized non-inferiority trial
Conventional fractionation (2 Gy x 25 fx) with sequential boost
VS
Hypofractionation (2.67 x 15 fx) with concomitant boost
• Closed 6/20/14
• Over-accrued 2354
ClinicalTrials.gov
NCT01349322
![Page 72: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/72.jpg)
Accelerated Partial Breast Irradiation
![Page 73: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/73.jpg)
Accelerated Partial Breast Irradiation
Starting to see maturation of the modern
randomized trials
GEC-ESTRO
Interstitial brachytherapy
Targit A
IORT photons
ELIOT
IORT electrons
RAPID
External beam photons
![Page 74: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/74.jpg)
GEC-ESTRO
• Prospective, randomized non-inferiority trial
– 3% non-inferiority margin
– Primary endpoint: IBTR
• Primary < 3.0 cm, N0 (micromets allowed)
• Randomization
– 50 Gy/25 fx whole breast
– Insterstitial brachytherapy
HDR: 4 Gy x 8 or 4.3 Gy x 7
PDR: 0.6 Gy-0.8 Gy to 50 Gy
Strnad, et al Lancet 2015 epub ahead of print
![Page 75: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/75.jpg)
Patient Characteristics
APBI (n=633) WBI (n=551) P-value
Age (years, median) 62 (40-92) 62 (40-85) 0.86
Menopausal status
pre 108 (17%) 92 (17%)0.93
post 525 (83%) 459 (83%)
Tumor size (mm, range) 12 (9-30) 12 (9-30) 0.19
Margin (mm, range) 8 (2-40) 7 (2-25) 0.39
Grade
1 248 (39%) 217 (39%)
0.552 319 (50%) 288 (52%)
3 57 (9%) 42 (8%)
Systemic Therapy
Yes 572 (90%) 505 (92%)0.63
No 59 (9%) 46 (8%)
Strnad, et al Lancet 2015 epub ahead of print
![Page 76: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/76.jpg)
Ipsilateral Breast Recurrence
Strnad V, et al
Lancet 2015
epub ahead of print
![Page 77: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/77.jpg)
Disease-Free Survival
Strnad, et al Lancet 2015 epub ahead of print
![Page 78: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/78.jpg)
GEC-ESTRO
• Results still early
– Late recurrences seen with luminal A
disease
– Long-term toxicity and cosmetic outcome
• Are these patients that don’t need
treatment?
• Interstitial will likely not be routinely
used in the majority of centers in the US
Strnad, et al Lancet 2015 epub ahead of print
![Page 79: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/79.jpg)
External beam whole breast
40 Gy-5 Gy in 15-25 fractions +/-
boost (10-16 Gy in 5-8 fractions)
IORT: 20 Gy at surface
*If high risk, add 45-50 Gy whole breast
(lobular carcinoma, EIC, <1 mm margin)
Can be at time of surgery, or delayed
Targeted Intraoperative RT (TARGIT)50 kv x-rays
Vaidya JS et al, Lancet 2014 383(9917):603-13
N= 3451
Multi-institutional
Accrued 200-2012
Age >45
Unifocal
![Page 80: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/80.jpg)
TARGIT: Low Risk Patients
• Median age: 63
• <2.0 cm 86%
• Grade I/II 84%
• Node negative 83%
• Hormonal therapy 66%
Chemotherapy 12%
Vaidya JS et al, Lancet 2014 383(9917):603-13
![Page 81: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/81.jpg)
TARGIT: Results
• Follow-up:
• Median: 29 months
• minimum of 4 years: 2020 patients
• minimum of 5 years: 1222 patients
• 5-year IBTR: 3.3% TARGIT vs 1.3% WBRT
• HR 2.07 (95% CI 1.01-4.25)
• Within pre-specified non-inferiority
margin (2.5%)
Vaidya JS et al, Lancet 2013. epub ahead of print
Vaidya JS et al, Lancet 2014 383(9917):603-13
![Page 82: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/82.jpg)
TARGIT: Results
• Concurrent with lumpectomy:
• 2.1% TARGIT vs 1.1% WBRT (p=0.31)
• Delayed after lumpectomy
• 5.4% vs 1.7% (p=0.069)
• Overall breast cancer mortality similar– 2.6% vs 1.9% (p=0.56)
• Decreased non-breast cancer deaths– 1.4% vs 3.5% (p=0.008)
Vaidya JS et al, Lancet 2013. epub ahead of printVaidya JS et al, Lancet 2014 383(9917):603-13
![Page 83: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/83.jpg)
Intraoperative Radiotherapy versus External
Radiotherapy for Early Breast Cancer (ELIOT)
• EORTC randomized trial of WBRT and IORT
(electrons)
• IORT: 21 Gy x 1
• WBRT: 2 Gy x 25 WB + 2 Gy x 5 boost
• Primary endpoint: IBTR
• Equivalence trial with a 7.5% equivalence
margin
Veronesi U, Lancet Oncol 2013 Dec;14(13):1269-77
![Page 84: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/84.jpg)
Patient
Characteristics
Veronesi U, Lancet Oncology 14 (13), 2013Veronesi U, Lancet Oncol 2013 Dec;14(13):1269-77
![Page 85: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/85.jpg)
Patient
Characteristics
Veronesi U, Lancet Oncology 14 (13), 2013Veronesi U, Lancet Oncol 2013 Dec;14(13):1269-77
![Page 86: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/86.jpg)
Patient
Characteristics
Veronesi U, Lancet Oncology 14 (13), 2013Veronesi U, Lancet Oncol 2013 Dec;14(13):1269-77
![Page 87: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/87.jpg)
ELIOT: Results
• N = 1305
• Median follow-up 5.8 years
• IBTR
– WB: 0.4%
– IORT: 4.4 % (HR 9.3; 95% CI 3.3 to 26.3)
Veronesi U, Lancet Oncol 2013 Dec;14(13):1269-77
![Page 88: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/88.jpg)
IBTR
Overall Survival
Veronesi U, Lancet Oncology 14 (13), 2013Veronesi U, Lancet Oncol
2013 Dec;14(13):1269-77
![Page 89: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/89.jpg)
Predictors of Recurrence in IORT Group
Factor IBTR P-value
Path Size (cm)
<1.0 1.9
1.0 to 1.5 4.2
1.5 – 2.0 4.7
>2.0 10.9 P=0.006
Grade
1 1.1
2 3.8
3 11.9 P=0.0003
Subtype
Luminal A 1.4
Luminal B 4.9
Her2 pos 5.9
Triple negative 18.9 P=0.001
Veronesi U,
Lancet Oncology
14 (13), 2013
Veronesi U et al,
Lancet Oncol
2013
Dec;14(13):1269-77
![Page 90: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/90.jpg)
RAPID: WB vs APBI
• N=2135
• Median follow-up: 36 months
• 3d CRT APBI (38.5/10 fx BID)
VS
• WB (42.5 in 16 fx or 50 in 25 fx +/- boost)
Olivotto, IA, et al. J Clin Oncol. 2013 31(32)
![Page 91: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/91.jpg)
Three and Five Year Toxicity and
Cosmetic Assessments
Olivotto, IA, et al. J Clin Oncol. 2013 31(32)Olivotto, IA, et al. J Clin Oncol. 2013 31(32)
![Page 92: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/92.jpg)
Three and Five-year Cosmetic Results
Olivotto, IA, et al. J Clin
Oncol. 2013 31(32)
Olivotto, IA, et al.
J Clin Oncol
2013 31(32)
![Page 93: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/93.jpg)
Late Radiation Toxicity
Olivotto, IA, et al. J Clin
Oncol. 2013 31(32)
Olivotto, IA, et al.
J Clin Oncol.
2013 31(32)
![Page 94: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/94.jpg)
ASTRO Consensus Statement
Suitable* Cautionary** Unadvisable***
Age >60 50-59 <50
Size <2 cm 2.1-3.0 cm >3.0 cm
LVI Negative Limited Extensive
Margin >2 mm Close; <2 mm Positive
Histology Ductal Lobular
DCIS Not pure DCIS DCIS <3 cm DCIS >3 cm
Nodes N0, N0i+ Node positive
ER Positive Negative
Smith BD et al. IJROBP 74(4), 2009
* Acceptable outside of a clinical trial
** ”Caution and concern in the use of APBI”*** ”Not warranted outside of a study”
![Page 95: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/95.jpg)
Modern Phase III Trials of PBI vs WBRT
Institution/Trial
Target
(yrs of
accrual)
Control
Arm
Experimental
Arm
European Institute of
Oncology
ELIOT
1200
(2000-2007)
WBI (50 Gy in 25 fx) ± 10 Gy
Boost
IORT (21 Gy in 1 fx, using electrons
up to 9 MeV)
TARGIT-A3451
(2000-2012)
WBI 40-56 Gy ± 10-16 Gy
boostIORT (20 Gy in 1 fx, low energy -rays)
*NSABP B 39/RTOG 0413
Closed to
accrual 4/13;
n=4216
50-50.4 Gy WBI
± 10-16 Gy Boost
(1) MIB (34 Gy in 10 fx), or
(2) MammoSite (34 Gy in 10 fx) or
(3) 3D-CRT (38.5 Gy in 10 fx)
French SHARE1170
(2004-2009)
WBI (50 Gy in 25 fx) + 16 Gy
Boost
WBI (40 Gy in 15 fx; or 42.5
in 16 fx)
3d-CRT (40 Gy in 10 fx, BID)
*Medical Research Council –
UK IMPORT LOW
1935
(2007-2010) WB 2.67Gy X 15
(1) WB 2.4Gy X 15
(2) PB 2.67Gy X 15
(3) PB only 2.67Gy X 15
*Ontario Clinical Oncology
Group- Canadian Trial
RAPID
2128
(2006-
7/2011)
WBI ± 10 Gy boost:
(1) 42.5 Gy in 16 fx for small
breasts or
(2) 50 Gy in 25 fx for large
breasts
3D CRT only
(38.5 Gy in 10 fx)
![Page 96: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/96.jpg)
The Nodes
![Page 97: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/97.jpg)
ACOSOG Z-11
• Patients– Clinical T1-2 N0
– 1 or 2 positive SN
– No gross ECE
• Treatment:
– Lumpectomy with whole breast irradiation
• Dose/precise fields not specified
– Adjuvant systemic therapy by choice (97%)
Guiliano A et al JAMA 2011 305: 569
![Page 98: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/98.jpg)
ACOSOG Z-11: Patients
cALND SNB Alone
# Patients 420 436
Age, median 56 yrs 54 yrs
T size, median 1.7 cm 1.6 cm
ER/PR+ 82% 82%
Grade 3 29% 28%
Guiliano A et al JAMA 2011 305: 569
![Page 99: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/99.jpg)
Outcomes of Z11(Median f/u: 6.3 years)
Recurrence Type ALND (420) SLNB only (436)
Locoregional (%) 4.1 2.8
Local 3.6 1.8
Axillary 0.5 0.9
DFS (%) 91.8 92.5
OS (%) 83.9 82.2
Giuliano A et al, Ann Surg. 2010 252(3):426-32
Giuliano A et al, JAMA. 2011 305(6):569-75
All comparisons non-significant
![Page 100: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/100.jpg)
Findings on cALND in Z-11
• 46% of positive sentinel nodes were
micromets
• Only 106 (27.4%) of patients treated
with cALND had additional positive
nodes beyond the SN
• This is a highly select group
Guiliano A et al JAMA 2011 305: 569
![Page 101: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/101.jpg)
Axillary
LN
Lumpectomy
Cavity
Axillary Vein
Standard
Superior
Border
Radiation Fields in ACOSOG Z0011
• 11% did not receive RT
• 228 patients (28.5%) had evaluable RT records:
50% received high tangents
19% had a separate nodal field
No difference between arms
High vs Standard Tangent
Fields
Jagsi R, J Clin Oncol 32(32), 2014
![Page 102: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/102.jpg)
IBCSG 23-01: ALND vs SN Only
for Micrometastases
• cT1-T2, micromets in 1-2 SNs
(H+E or IHC)
• Accrued: 934 (target 1950) between
2001-2010
• Median F/U of 5 years
Galimberti et al Lancet Oncol 2013;14:297
![Page 103: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/103.jpg)
IBCSG 23-01: Characteristics
ALND (n=464) SLNB (n=467)
Median Age 53 yrs (23-81) 54 yrs (26-81)
T <3 cm 91% 93%
ER + 88% 91%
Systemic Rx 95% 97%
Mastectomy 9% 9%
Median # SN 2 (1-9) 1 (1-8)
Additional positive
nodes59 (13%) 12 (3%)
RT after BCS: • 70% External Beam
• 19% Intraop
• 9% combination
98% 97%
![Page 104: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/104.jpg)
IBCSG 23-01: Results
RecurrenceALND
(n=464)
SLNB
(n=467)
Local 10 (2%) 8 (2%)
Regional 1 (<1%) 5 (1%)
Distant 34 (7%) 25 (5%)
5Y DFS 85%* 88%*
5Y OS 96% 96%
*Log rank p=0.16
non-inferiority p=0.004Galimberti et al Lancet Oncol 2013;14:297
![Page 105: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/105.jpg)
AMAROS: Study Design
CT1-2, N0
3381 SN negative
1425 SN positive
axRT
(n=681)
cALND
(n=744)®
Rutgers, E. Lancet Oncology 2014; 15:303-10
![Page 106: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/106.jpg)
Axillary RT in AMAROS
• Started <12 wks after SNB
• 25 x 2Gy or equivalent
• Level I, II, III and medial
SCV
• Additional AxRT: >4
positive nodes (in
dissection arm)Figure adapted from Harris, J
Rutgers, E. Lancet Oncology 2014; 15:303-10
![Page 107: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/107.jpg)
cALND
n=744
AxRT
n=681
5-yr Axillary
recurrence
0.54%
(n=4)
1.03%
(n=7)
5Y DFS 87% 83%
5Y OS 94% 94%
5 yr Clinical
Lymphedema23% 11%
AMAROS Results(Median f/u 6.1 years)
P<0.0001
Rutgers, E. Lancet Oncology 2014; 15:303-10
![Page 108: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/108.jpg)
Disease-Free and Overall Survival
Rutgers, E. Lancet Oncology 2014; 15:303-10
![Page 109: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/109.jpg)
Substituting RT for Surgery
• All of these trial indicate RT can
substitute for cALND
– At least in fairly select patients
• But what volume to irradiate?
– Tangents alone?
– High tangents?
– Supraclav?
– IMN?
![Page 110: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/110.jpg)
MA.20 Randomization
Node positive, or high risk node-
negative, s/p breast conservation
Whole breast radiationVS
Whole breast and regional nodal radiation
Whelan TJ et al, NEJM 2015; 373:307-316
![Page 111: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/111.jpg)
Eligibility
• Node positive
• High risk node negative
– >5 cm or
– >2 cm and <10 nodes removed
And grade 3 or LVI positive or ER negative
• Chemotherapy and/or endocrine
therapy required
Whelan TJ et al, NEJM 2015; 373:307-316
![Page 112: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/112.jpg)
MA.20 RT Details
• Whole breast: 50 Gy/25 fx
– Cone down: 10-16 Gy (e- or brachy)
• IMNs treated with either partially wide tangents or anterior field (electron and photon
combination)– 50 Gy/25 fx
• SCV/axilla (AP or AP/PA)– Full axilla for >3 positive nodes or <10 dissected
– 45 Gy (for AP/PA), 50 Gy (AP)
Whelan TJ et al, NEJM 2015; 373:307-316
![Page 113: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/113.jpg)
Baseline Characteristics
WBI
N=916
WBI + RNI
N=916
Age (mean) 52.7 53.9
Axillary nodes removed (mean) 12.3 12.4
Node –ve 89 (10) 89(10)
Node +ve (1-3) 780 (85) 776 (85)
Tumor size > 2 cm 416 (45) 457 (50)
Grade III 387 (42) 390(43)
ER –ve 235 (26) 232 (25)
Adj chemotherapy 829 (91) 830 (91)
Adj endocrine therapy 705 (77) 700 (76)
Boost irradiation 221 (24) 206 (22)
in 39%
Whelan TJ et al, NEJM 2015; 373:307-316
![Page 114: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/114.jpg)
Baseline Characteristics
WBI
N=916
WBI + RNI
N=916
Age (mean) 52.7 53.9
Axillary nodes removed (mean) 12.3 12.4
Node –ve 89 (10) 89(10)
Node +ve (1-3) 780 (85) 776 (85)
Tumor size > 2 cm 416 (45) 457 (50)
Grade III 387 (42) 390(43)
ER –ve 235 (26) 232 (25)
Adj chemotherapy 829 (91) 830 (91)
Adj endocrine therapy 705 (77) 700 (76)
Boost irradiation 221 (24) 206 (22)
in 39%
Whelan TJ et al, NEJM 2015; 373:307-316
![Page 115: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/115.jpg)
Baseline Characteristics
WBI
N=916
WBI + RNI
N=916
Age (mean) 52.7 53.9
Axillary nodes removed (mean) 12.3 12.4
Node –ve 89 (10) 89(10)
Node +ve (1-3) 780 (85) 776 (85)
Tumor size > 2 cm 416 (45) 457 (50)
Grade III 387 (42) 390(43)
ER –ve 235 (26) 232 (25)
Adj chemotherapy 829 (91) 830 (91)
Adj endocrine therapy 705 (77) 700 (76)
Boost irradiation 221 (24) 206 (22)
in 39%
Whelan TJ et al, NEJM 2015; 373:307-316
![Page 116: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/116.jpg)
Whelan TJ et al. N Engl J Med 2015;373:307-316
10-Year Kaplan–Meier Estimates of Survival.
Median follow-up 9.5 years
![Page 117: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/117.jpg)
Ten-year Results (n=1832)
10-YrNo Nodal
RT
Nodal
RTHR
p-
value
LRR* 6.8% 4.3% 0.59 .009
DFS 77.0% 82.0% 0.76 .01
OS 81.8% 82.8% 0.91 .38
Whelan TJ et al, NEJM 2015; 373:307-316
*isolated
![Page 118: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/118.jpg)
Whelan et al, NEJM, 2015; 373:307-316
MA-20: Hazard Ratios for Overall Survival
![Page 119: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/119.jpg)
LRR +/- RT by Subtype Approximation
Danish 82 b and c
Kyndi et al. JCO 2008; 26: 1419-1426
ER+
HER2-
ER+HER2+
Triple Neg
ER-HER2+
![Page 120: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/120.jpg)
Adverse Events
• Any lymphedema increased from
4.5% to 8.4%; p = 0.001
• Radiation pneumonitis increased from
.2% to 1.2%; p = 0.01
–All grade 2
• Major cardiac event 0.4 vs 0.9, p= 0.26
*NCI – Common toxicity criteria v2 1998
Whelan TJ et al, NEJM 2015; 373:307-316
![Page 121: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/121.jpg)
EORTC Phase III Trial 22922/10925n= 4,004
Stage I-III, pN+ or pN- w/ central/medial
ARM 1: No nodal RT
®
ARM 2: IM and supraclav RT
Poortmans PM et al. N Engl J Med 2015;373:317-327
![Page 122: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/122.jpg)
Poortmans PM et al. N Engl J Med 2015;373:317-327
![Page 123: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/123.jpg)
Poortmans PM et al. N Engl J Med 2015;373:317-327
![Page 124: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/124.jpg)
Poortmans PM et al. N Engl J Med 2015;373:317-327
Distant Disease-free and Overall Survival
Median
follow-up:
10.9 years
P=0.02
P=0.06
![Page 125: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/125.jpg)
Poortmans PM et al.
N Engl J Med
2015;373:317-327
Hazard Ratio for Death, According to Subgroups
![Page 126: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/126.jpg)
Multicenter French Randomized Trial
• Randomization: CW, SCV +/- IM
• N=1407
• Eligibility:
– Mastectomy, larger than 1.0 cm
– Any node positive
– Medial/central with or without positive nodes
• Technique: First 5 interspaces
• Powered for 10% difference in OS
Hennequin et al IJROBP 86(5), 2013
![Page 127: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/127.jpg)
Key Patient Characteristics
No IM RT (%) IM RT (%)
Location: Lateral 236 (36) 232 (35)
Medial 426 (64) 440 (65)
Nodal status: N0 162 (24) 169 (25)
N+ 500 (76) 503 (75)
Grade: I/II 349 (53) 360 (54)
III 154 (23) 164 (24)
Adj chemotherapy 402 (61) 410 (61)
Adj hormonal therapy 348 (53) 350 (52)
Hennequin et al IJROBP 86(5), 2013
![Page 128: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/128.jpg)
Hennequin: 10 Year Results
OutcomeNo IM RT
(%)
IM RT
(%)p
OS 59.3 62.6 0.8
DFS 53.2 49.9 0.35
LR as first
event9.8 9.2 NS
Cardiac
Events2.2 1.7 NS
Hennequin et al IJROBP 86(5), 2013
![Page 129: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/129.jpg)
The Danish Experience
• Prospective cohort study, 2003-2007
• Node positive (macroscopic), younger
than age 70
• All received periclavicular and chest or
breast RT
• LT-sided: RT without IMN (n=1586)
• RT-sided: RT with IMN (n=1486)
Thorsen LBJ et al, J Clin Oncol, epub 2015
![Page 130: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/130.jpg)
Key Pt/Tx Characteristics
(median follow-up 8.9 years)
• Median age 56
• Mastectomy 65%; BCT 35%
• ER Positive 80%
• Positive axillary nodes:
– 1-3 59%
– 4-9 26%
– >10 15%
• High grade 28%
Thorsen LBJ et al, J Clin Oncol, epub 2015
![Page 131: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/131.jpg)
Thorsen LBJ et al, J Clin Oncol, epub 2015
Overall Survival, HR 0.82; p=0.005
Breast Cancer Mortality, HR 0.85; p=0.03
Distant Recurrence, HR 0.89; p=0.07
75.9%
72.2%
![Page 132: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/132.jpg)
More Questions (few answers)
• What is the relative benefit of IM vs SCV RT
– Does it make sense to treat SCV alone in
patients with ‘difficult’ anatomy
• Which subgroups are most likely to benefit
– ER negative?
– HER2+
– One positive node?
• What is the long-term risk of increased lung
V20 and low-dose cardiac RT?
![Page 133: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/133.jpg)
Post-Mastectomy Radiation
![Page 134: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/134.jpg)
Meta-analysis of PMRT Trials
• 22 trials with 8135 women treated
with mastectomy + axillary surgery
+/- PMRT
• Adjuvant systemic therapy was
used in the majority of patients
• RT to chest wall, SCV +/- axilla,
internal mammary nodes
Lancet 2014;383(9935):2127-35
![Page 135: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/135.jpg)
Absolute Benefits of PMRT (n=8135)
11.5%
8.8%
1-3+
> 4+
7.9%
9.3%
16.5%
19.1%
Lancet 2014;383(9935):2127-35
![Page 136: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/136.jpg)
Impact of Number of Involved Nodes
Lancet 2014;383(9935):2127-35
![Page 137: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/137.jpg)
McBride et al, MDACC
• Retrospective review; n =1027
• T1, T2; 1-3 nodes
• Early era: 1978-1997
– before taxanes, AI
• Late era: 2000-2007
McBride et al, IJROBP Volume 89, Issue 2, 2014, 392–398
![Page 138: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/138.jpg)
McBride et al, IJROBP Volume 89, Issue 2, 2014, 392–398
N=505
1978-1997
9.5% at 5 years
3.4% at 5 years
![Page 139: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/139.jpg)
McBride et al, IJROBP Volume 89, Issue 2, 2014, 392–398
N=522
2000-2007
2.8% at 5 years
4.2% at 5-years
![Page 140: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/140.jpg)
Effective Systemic Therapy Improves LRR
• Chemotherapy improves LRR beyond
adjuvant RT alone
– EBCTCG
• Clarke et al. Lancet 2005; 365:1687
– NSABP• Anderson SJ et al. JCO 2005; 27
• Incremental improvements in systemic
therapy further lower LRR– Addition of taxanes
– Addition of trastuzumab
![Page 141: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/141.jpg)
TA
MO
XIF
EN
CH
EM
OT
HE
RA
PY
EBCTCG Overview. Lancet 2005;365:1687
![Page 142: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/142.jpg)
10-Year LR in NSABP trials for
node-negative tumors
TrialER
Status
10-Year
LR (%)
B-13 No Chemo - 13.3
B-13 Chemo - 3.5
B-14 No Tamoxifen + 11.0
B-14 Tamoxifen + 3.6
Anderson SJ et al. J Clin Oncol 2005:27;2466
![Page 143: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/143.jpg)
Impact of Taxanes on LRR
![Page 144: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/144.jpg)
Impact of H on LRR: First Events
Patients B-31 N9831 (NCCTG)
Control Trastuzumab Control Trastuzumab
All patients 872 864 807 808
Alive and event-free 701 781 717 758
Any First event 171 83 90 50
Local or Reg Recurrence
35 15 22 12
Distant Recurrence111 60 63 30
CBC 6 2 0 1
Second Primary 15 2 3 3
Death Without Disease
4 4 2 4
Romond et al NEJM 353:16, 2005
![Page 145: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/145.jpg)
• Preop AC arm from B-18 and the preop AC +/- T
arms from B-27
• N= 1,071 mastectomy patients
• SNB performed after chemotherapy
• pCR was defined as no residual invasive
disease (DCIS permitted)
Can Systemic Therapy Select
Patients who Don’t Benefit from RT? NSABP Experience
Mamounas E et al JCO 2012 30: 3960
![Page 146: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/146.jpg)
Predictors of LRR after Mastectomy: MVA
• Clinical tumor size at presentation
• Clinical node status at presentation
• Path node status after chemotherapy
• Path response in the breast
Both the initial clinical and the final path
stage must be used to determine LR risk
Mamounas E et al JCO 2012 30: 3960
![Page 147: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/147.jpg)
Mamounas et al: MVA
Variable HR 95% CI P
cT: > 5 vs < 5 cm 1.58 1.12 – 2.23 .0095
cN+ vs cN- 1.53 1.08 - 2.18 .017
pCR nodes vs
Complete pCR2.21 0.77 – 6.30 < .001
Node positive vs
Complete pCR 4.48
1.64 –
12.21< .001
Mamounas E et al JCO 2012 30: 3960
![Page 148: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/148.jpg)
Mamounas et al: MVA
Variable HR 95% CI p
cT: > 5 vs < 5 cm 1.58 1.12 – 2.23 .0095
cN+ vs cN- 1.53 1.08 - 2.18 .017
pCR nodes vs
Complete pCR2.21 0.77 – 6.30 < .001
Node positive vs
Complete pCR 4.48
1.64 –
12.21< .001
Mamounas E et al JCO 2012 30: 3960
![Page 149: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/149.jpg)
10-Year Risk of LRR
Mastectomy,
Clinical T ≤ 5 cm
Mastectomy
Clinical T > 5 cm
Mamounas E et al JCO 2012 30: 3960
![Page 150: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/150.jpg)
NSABP B-51/RTOG 1304
Clinical T1–3, N1
Positive Axillary Nodes by FNA or Core
Accrual goal – 1636 patients over 5 years
NEOADJUVANT THERAPY1 SURGERY2
1Minimum 12 weeks, trastuzumab when appropriate2Path Documentation of Negative Axillary Nodes (by ALND or by SLNBx ± ALND)
RANDOMIZATION
Mastectomy
Breast Conservation
PMRT
No PMRT
Breast alone
Breast and Regional Nodes
![Page 151: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/151.jpg)
DCIS
![Page 152: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/152.jpg)
Randomized Trials of Excision +/- RT
N FU E alone E + RT
NSABP B-17 814 17 y 35% 20%invasive: 20% 11%
DCIS: 15% 9%
EORTC 1010 15.8 y 30% 17%invasive: 50% 56%
DCIS: 50% 44%
UK 1030 12.7 y 19% 7%invasive: 7% 4%
DCIS: 12% 3%
Swedish 1067 8 y 27% 12%invasive: 12% 7%
DCIS: 15% 5%
![Page 153: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/153.jpg)
EBCTCG Meta-Analysis: DCIS
Correa, JNCI Monogr 41:162-177, 2010
N=3729
![Page 154: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/154.jpg)
RTOG 9804: Details
• Randomized, RT vs No RT; 1998-2006
• Low or intermediate grade
• Smaller than 2.5 cm; margins >3mm
• N = 636 (1790 planned accrual)
• Tam optional (62%)
• Median follow-up 7.1 years
McCormick et al. JCO 2015;33:709-715
![Page 155: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/155.jpg)
RTOG 9804: Results
McCormick B, JCO 33(7), 2015
![Page 156: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/156.jpg)
DCIS: Omission of RTECOG 5194
• Study design– Single arm, excision without radiation
– Tam optional (30%)
– At least 3 mm margin or negative re-excision
• Low risk: – Low or intermediate grade
– Smaller than 2.5 cm
• High risk: – High grade, smaller than 1.0 cm
Solin LJ, JCO epub ahead of print, 2015
![Page 157: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/157.jpg)
ECOG 5194, Low Risk
Any Ipsi Breast Event (%) Invasive Ipsi Breast Event (%)
5 years 6 (4.0-8.1) 2.7 (1.3-4.1)
7 years 9.5 (7.0-12.0) 4.8 (2.9-6.6)
10 years 12.5 (9.5-15.4) 6.4 (4.2-8.6)
12 years 14.4 (CI 11.2-17.6) 7.5 (5.1-10.0)
N=561
Median follow-up 12.3 years
Solin LJ, JCO epub ahead of print, 2015
![Page 158: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/158.jpg)
ECOG 5194, High Risk (High grade, Smaller than 1.0 cm)
Any Ipsi Breast Event (%) Invasive Ipsi Breast Event (%)
5 years 15 (7.7-21.7) 5.3 (0.8-9.7)
7 years 18.2 (10.6-25.8) 7.6 (2.2-13.0)
10 years 24.6 (15.7-33.4) 13.4 (5.9-20.9)
12 years 24.6 (15.7-33.4) 13.4 (5.9-20.9)
Solin LJ, JCO epub ahead of print, 2015
N=104
![Page 159: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/159.jpg)
Oncotype DX DCIS Score
• 12/21 genes from the Oncotype DX Recurrence Score
• Continues score (0-100)
• 3 specified risk groups– Low (<39)
– Int (39-54)
–High (>54)
Solin LJ, JNCI 2013, 105
7 cancer-related genes 5 reference genes
![Page 160: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/160.jpg)
Oncotype DCIS Score: ECOG 5194
<2.5 cm,
grade I or II
<1.0 cm,
grade III
Margins > 3mm
Solin LJ, et al JNCI 2013, 105
![Page 161: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/161.jpg)
Ontario DCIS ValidationN=718
0 2 4 6 8 10
Rakovitch et al Br Res Treat, 2015, 152
![Page 162: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/162.jpg)
Conclusions
• Breast conservation is an appropriate option for
most women with early-stage disease with
outstanding long-term local control
• We are beginning to understand tumor biology as it
relates to local control, and hopefully this will allow
omission of RT in select patients
• Hypofractionation is the best option for most women
with early-stage disease undergoing BCT
• Beginning to see the maturation of the APBI trials.
Over the next 5 years I think we'll have a much better
idea of long term toxicity and efficacy
![Page 163: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/163.jpg)
Conclusions
• Breast conservation is an appropriate option for
most women with early-stage disease with
outstanding long-term local control
• We are beginning to understand tumor biology as it
relates to local control, and hopefully this will allow
omission of RT in select patients
• Hypofractionation is the best option for most women
with early-stage disease undergoing BCT
• Beginning to see the maturation of the APBI trials.
Over the next 5 years I think we'll have a much better
idea of long term toxicity and efficacy
![Page 164: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/164.jpg)
Conclusions
• Breast conservation is an appropriate option for
most women with early-stage disease with
outstanding long-term local control
• We are beginning to understand tumor biology as it
relates to local control, and hopefully this will allow
omission of RT in select patients
• Hypofractionation is the best option for most women
with early-stage disease undergoing BCT
• Beginning to see the maturation of the APBI trials.
Over the next 5 years I think we'll have a much better
idea of long term toxicity and efficacy
![Page 165: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/165.jpg)
Conclusions
• Breast conservation is an appropriate option for
most women with early-stage disease with
outstanding long-term local control
• We are beginning to understand tumor biology as it
relates to local control, and hopefully this will allow
omission of RT in select patients
• Hypofractionation is the best option for most women
with early-stage disease undergoing BCT
• Beginning to see the maturation of the APBI trials.
Over the next 5 years I think we'll have a much better
idea of long term toxicity and efficacy
![Page 166: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/166.jpg)
Conclusions (continued)
• Axillary dissection is not warranted for many (?most)
patients with 1-2 positive sentinel nodes
• Appropriate nodal fields still in evolution, but my bar
to treat the nodes has dropped
• Whom to treat with PMRT is still unclear, particularly
with modern systemic therapy, but overall LRR is
lower than previously appreciated
• Clinically node positive patients who achieve pCR
may not need RT (please enroll on B-51)
• DCIS: Hope for improved molecular characterization
of disease, and ability to predict LR
![Page 167: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/167.jpg)
Conclusions (continued)
• Axillary dissection is not warranted for many (?most)
patients with 1-2 positive sentinel nodes
• Appropriate nodal fields still in evolution, but my bar
to treat the nodes has dropped
• Whom to treat with PMRT is still unclear, particularly
with modern systemic therapy, but overall LRR is
lower than previously appreciated
• Clinically node positive patients who achieve pCR
may not need RT (please enroll on B-51)
• DCIS: Hope for improved molecular characterization
of disease, and ability to predict LR
![Page 168: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/168.jpg)
Conclusions (continued)
• Axillary dissection is not warranted for many (?most)
patients with 1-2 positive sentinel nodes
• Appropriate nodal fields still in evolution, but my bar
to treat the nodes has dropped
• Whom to treat with PMRT is still unclear, particularly
with modern systemic therapy, but overall LRR
seems to be lower than previously appreciated
• Clinically node positive patients who achieve pCR
may not need RT (please enroll on B-51)
• DCIS: Hope for improved molecular characterization
of disease, and ability to predict LR
![Page 169: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/169.jpg)
Conclusions (continued)
• Axillary dissection is not warranted for many (?most)
patients with 1-2 positive sentinel nodes
• Appropriate nodal fields still in evolution, but my bar
to treat the nodes has dropped
• Whom to treat with PMRT is still unclear, particularly
with modern systemic therapy, but overall LRR is
lower than previously appreciated
• Clinically node positive patients who achieve pCR
may not need RT (please enroll on B-51)
• DCIS: Hope for improved molecular characterization
of disease, and ability to predict LR
![Page 170: ASTRO Refresher Course 2016 Breast Cancer · ASTRO Refresher Course 2016 Breast Cancer ... – Core biopsy (not FNA) – Excisional biopsy if core biopsy not feasible • Breast-conserving](https://reader030.fdocuments.us/reader030/viewer/2022021420/5ad133567f8b9a665f8b478b/html5/thumbnails/170.jpg)
Conclusions (continued)
• Axillary dissection is not warranted for many (?most)
patients with 1-2 positive sentinel nodes
• Appropriate nodal fields still in evolution, but my bar
to treat the nodes has dropped
• Whom to treat with PMRT is still unclear, particularly
with modern systemic therapy, but overall LRR is
lower than previously appreciated
• Clinically node positive patients who achieve pCR
may not need RT (please enroll on B-51)
• DCIS: Hope for improved molecular characterization
of disease, and ability to predict LR